Clinical trial NCT01332786: Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Official title: Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Keywords: AML
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: University of Kansas
name: Memorial Sloan Kettering Cancer Center
name: University of California, Los Angeles
First posted: 2011-04-11
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether tigecycline is safe and which dosage is most effective in the treatment of patients with acute myeloid leukemia.

Detailed description: Relapsed and refractory hematologic malignancies have poor responses to standard therapy and are associated with a poor prognosis. For example, relapsed acute myeloid leukemia (AML) is a highly aggressive and resistant disease, particularly when associated with first complete response (CR) duration of less than 12 months. Thus, there is an urgent need for new agents in relapsed and refractory hematologic malignancies such as acute leukemia. In elderly patients, where the tolerance of aggressive induction therapy is often poor and curative options such as bone marrow transplantation HSCT are not available, the need for effective non-aggressive drug regimens for AML is even greater.

Tigecycline is a glycylcycline derivative of tetracycline. Tigecycline is currently indicated for the treatment of complicated skin and skin structure infections, and complicated intra-abdominal infections. This clinical trial is a Phase I dose escalation study of tigecycline in patients with relapsed or refractory AML or those with newly diagnosed disease not eligible for induction chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Diagnosis of relapsed or refractory AML for which all potentially curative or standard salvage therapy options have been exhausted; OR AML without prior treatment who are not eligible for induction chemotherapy as defined as age \> or equal to 80 or age \> 70 with poor risk cytogenetics (3 or more abnormalities, -5/del(5q), 3q abnormalities, or -7) or stable co-morbidities that would preclude induction chemotherapy such as LVEF less than 40% and/or DlCO less than 60% expected
* ECOG 0-2 performance status
* Biochemical values within the following range
* Serum creatinine \<2x upper limit of normal
* Total bilirubin \<1.5x upper limit of normal
* AST and ALT \<2x upper limit of normal
* Recovery from non-hematologic toxicity from prior chemotherapy
* Able and willing to provide informed consent

Exclusion Criteria:

* Allergy to tetracycline or minocycline
* Uncontrolled intercurrent illness such as uncontrolled diabetes or active uncontrolled infection
* Active systemic bacterial, fungal, or viral infection
* Concomitant use of linezolid or chloramphenicol that are known to inhibit mitochondrial protein synthesis
* Pregnant or breast feeding
* Known active CNS involvement with AML
* Neurologic symptoms related to uncontrolled illnesses or unexplained causes
* Psychiatric illness that would limit compliance with study
* Receiving systemic chemotherapy other than hydroxyurea to control circulating blast counts. Concomitant hydroxyurea is permitted, but only in the first cycle of therapy
* Prior therapy with tigecycline as an anti-cancer therapy or any use of the drug in the last month
* Use of other investigational anti-leukemic therapy within 14 days of registration

Primary outcomes:
measure: Toxicity evaluated according to CTCAE version 4.03
timeFrame: Reviewed at each visit and assessed at the end of each 3-week cycle
Secondary outcomes:
measure: Response rate assessment of tigecycline through laboratory assessments
timeFrame: Assessed at the end of each 3-week cycle for the study duration
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
city: Kansas City
country: United States
facility: The University of Kansas Medical Center
state: Kansas
city: Toronto
country: Canada
facility: Princess Margaret Hospital
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Aaron Schimmer, MD
role: STUDY_DIRECTOR
References: